Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism

Bone

Volumn 49, Issue 4, 2011, Pages 733-742

  Henneicke, Holger ^a,b   Herrmann, Markus ^a   Kalak, Robert ^a   Brennan Speranza, Tara C ^a   Heinevetter, Uta ^a,b   Bertollo, Nicky ^c   Day, Robert E ^d   Huscher, Dörte ^a,e   Buttgereit, Frank ^b   Dunstan, Colin R ^a,f   Seibel, Markus J ^a,g   Zhou, Hong ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ROYAL PERTH HOSPITAL   (Australia)

^e German Rheumatism Research Centre   (Germany)

^f UNIVERSITY OF SYDNEY   (Australia)

^g ANZAC Research Institute   (Australia)

Author keywords

Cortical bone; Glucocorticoids; Hydroxysteroid dehydrogenase; Mouse model; Osteoblasts

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; COLLAGEN TYPE 1; COLLAGEN TYPE 1A1; CORTICOSTERONE; OSTEOCALCIN; PHOSPHATASE; PLACEBO; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE METABOLISM; BONE STRUCTURE; BONE TURNOVER; CELL FUNCTION; CELL STRUCTURE; CONTROLLED STUDY; CORTICAL BONE; DRUG ACTIVITY; DRUG EXPOSURE; ENDOCORTICAL BONE; LOW DRUG DOSE; LUMBAR VERTEBRA; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PERICORTICAL BONE; SIGNAL TRANSDUCTION; THICKNESS; TIBIA; TRABECULAR BONE; TREATMENT DURATION;

ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE REMODELING; CORTICOSTERONE; GLUCOCORTICOIDS; MALE; MICE; OSTEOBLASTS; SPINE; SURFACE PROPERTIES; TIBIA;

EID: 80052295121     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.06.013     Document Type: Article

References (29)

1. Gounarides J.S., Korach-Andre M., Killary K., Argentieri G., Turner O., Laurent D. Effect of dexamethasone on glucose tolerance and fat metabolism in a diet-induced obesity mouse model. Endocrinology 2008, 149:758-766.
2. Buttgereit F., Burmester G.R., Lipworth B.J. Inflammation, glucocorticoids and risk of cardiovascular disease. Nat Clin Pract Rheumatol 2009, 5:18-19.
3. Perez P., Page A., Bravo A., Del Rio M., Gimenez-Conti I., Budunova I., Slaga T.J., Jorcano J.L. Altered skin development and impaired proliferative and inflammatory responses in transgenic mice overexpressing the glucocorticoid receptor. FASEB J 2001, 15:2030-2032.
4. Huscher D., Thiele K., Gromnica-Ihle E., Hein G., Demary W., Dreher R., Zink A., Buttgereit F. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009, 68:1119-1124.
5. Schakman O., Gilson H., Thissen J.P. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 2008, 197:1-10.
6. Saag K.G., Emkey R., Schnitzer T.J., Brown J.P., Hawkins F., Goemaere S., Thamsborg G., Liberman U.A., Delmas P.D., Malice M.P., Czachur M., Daifotis A.G. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998, 339:292-299.
7. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998, 102:274-282.
8. Rauch A., Seitz S., Baschant U., Schilling A.F., Illing A., Stride B., Kirilov M., Mandic V., Takacz A., Schmidt-Ullrich R., Ostermay S., Schinke T., Spanbroek R., Zaiss M.M., Angel P.E., Lerner U.H., David J.P., Reichardt H.M., Amling M., Schutz G., Tuckermann J.P. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab 2010, 11:517-531.
9. Leonard M.B., Feldman H.I., Shults J., Zemel B.S., Foster B.J., Stallings V.A. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 2004, 351:868-875.
10. Wetzsteon R.J., Shults J., Zemel B.S., Gupta P.U., Burnham J.M., Herskovitz R.M., Howard K.M., Leonard M.B. Divergent effects of glucocorticoids on cortical and trabecular compartment BMD in childhood nephrotic syndrome. J Bone Miner Res 2009, 24:503-513.
11. Gesina E., Tronche F., Herrera P., Duchene B., Tales W., Czernichow P., Breant B. Dissecting the role of glucocorticoids on pancreas development. Diabetes 2004, 53:2322-2329.
12. Cole T.J., Blendy J.A., Monaghan A.P., Krieglstein K., Schmid W., Aguzzi A., Fantuzzi G., Hummler E., Unsicker K., Schutz G. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev 1995, 9:1608-1621.
13. Zhou H., Mak W., Kalak R., Street J., Fong-Yee C., Zheng Y., Dunstan C.R., Seibel M.J. Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice. Development 2009, 136:427-436.
14. Sher L.B., Woitge H.W., Adams D.J., Gronowicz G.A., Krozowski Z., Harrison J.R., Kream B.E. Transgenic expression of 11beta-hydroxysteroid dehydrogenase type 2 in osteoblasts reveals an anabolic role for endogenous glucocorticoids in bone. Endocrinology 2004, 145:922-929.
15. Sher L.B., Harrison J.R., Adams D.J., Kream B.E. Impaired cortical bone acquisition and osteoblast differentiation in mice with osteoblast-targeted disruption of glucocorticoid signaling. Calcif Tissue Int 2006, 79:118-125.
16. Zhou H., Mak W., Zheng Y., Dunstan C.R., Seibel M.J. Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through Wnt signaling. J Biol Chem 2008, 283:1936-1945.
17. Kalak R., Zhou H., Street J., Day R.E., Modzelewski J.R., Spies C.M., Liu P.Y., Li G., Dunstan C.R., Seibel M.J. Endogenous glucocorticoid signalling in osteoblasts is necessary to maintain normal bone structure in mice. Bone 2009, 45:61-67.
18. Zebaze R.M., Ghasem-Zadeh A., Bohte A., Iuliano-Burns S., Mirams M., Price R.I., Mackie E.J., Seeman E. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 2010, 375:1729-1736.
19. Wang Q., Wang X.F., Iuliano-Burns S., Ghasem-Zadeh A., Zebaze R., Seeman E. Rapid growth produces transient cortical weakness: a risk factor for metaphyseal fractures during puberty. J Bone Miner Res 2010, 25:1521-1526.
20. Holzer G., von Skrbensky G., Holzer L.A., Pichl W. Hip fractures and the contribution of cortical versus trabecular bone to femoral neck strength. J Bone Miner Res 2009, 24:468-474.
21. Herrmann M., Henneicke H., Street J., Modzelewski J., Kalak R., Buttgereit F., Dunstan C.R., Zhou H., Seibel M.J. The challenge of continuous exogenous glucocorticoid administration in mice. Steroids 2009, 74:245-249.
22. Simanainen U., Lampinen A., Henneicke H., Brennan T.C., Heinevetter U., Harwood D.T., McNamara K., Herrmann M., Seibel M.J., Handelsman D.J., Zhou H. Long-Term corticosterone treatment induced lobe-specific pathology in mouse prostate. Prostate 2011, 71:289-297.
23. Buttgereit F., Zhou H., Kalak R., Gaber T., Spies C.M., Huscher D., Straub R.H., Modzelewski J., Dunstan C.R., Seibel M.J. Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serum-induced arthritis in vivo. Arthritis Rheum 2009, 60:1998-2007.
24. Weber A.J., Li G., Kalak R., Street J., Buttgereit F., Dunstan C.R., Seibel M.J., Zhou H. Osteoblast-targeted disruption of glucocorticoid signalling does not delay intramembranous bone healing. Steroids 2010, 75:282-286.
25. Okada Y., Nawata M., Nakayamada S., Saito K., Tanaka Y. Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. J Rheumatol 2008, 35:2249-2254.
26. Laan R.F., Buijs W.C., van Erning L.J., Lemmens J.A., Corstens F.H., Ruijs S.H., van de Putte L.B., van Riel P.L. Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content. Calcif Tissue Int 1993, 52:5-9.
27. Oakley R.H., Cidlowski J.A. Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids. J Biol Chem 2011, 286:3177-3184.
28. Kim H.J., Zhao H., Kitaura H., Bhattacharyya S., Brewer J.A., Muglia L.J., Ross F.P., Teitelbaum S.L. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006, 116:2152-2160.
29. Jia D., O'Brien C.A., Stewart S.A., Manolagas S.C., Weinstein R.S. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006, 147:5592-5599.